All In Biotech

Drug Trial Radar · NCT02019706

Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome

Last checked: Nov 20, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Feb 12, 2014

Primary completion

Dec 31, 2030

Study completion Dec 31, 2030

Sponsor

Sponsor type
NIH
First posted
Dec 24, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Between 10% and 15% of patients with endogenous hypercortisolism (Cushing syndrome) have ectopic (non-pituitary) production of adrenocorticotropin hormone (ACTH) that causes cortisol excess. In approximately 50% of these patients, the tumoral source of ACTH cannot be found initially despite very detailed and extensive imaging, including studies such as computed tomography, magnetic resonance imaging, and octreotide scan (Octreoscan) using the standard dose of indium- 111 pentetreotide (\[111In-DTPA-D-Phe\]-pentetreotide). The sensitivity and specificity of structurally based imaging studies depends on anatomic alterations and the size of the tumor. In contrast, positron emission tomography (PET) and somatostatin ligand imaging detect pathologic tissue based on physiologic and biochemical processes within the abnormal tissue. This protocol tests the ability of \[18F\]-L-3,4-dihydroxyphenylalanine (18F-DOPA) PET, and the somatostatin imaging analogue, 68Ga-DOTATATE-PET, to localize the source of ectopic ACTH production.

Conditions

  • ACTH
  • Cushing's Syndrome

Interventions

  • DOTATATE PET-CTRadiation

    68Ga-DOTATATE PET/CT

  • F-DOPA PET CTRadiation

    68Ga-DOTATATE PET/CT

  • CT scanRadiation

    routine CT scan

  • Routine MRI scanDiagnostic test

    routine 1.5 or 3T MRI scan

  • Gated MRI scanDiagnostic test

    Cardiac gated MRI scan

  • 68Ga-DOTATATEDrug

    68Ga-DOTATATE radioligand

  • 18F-DOPADrug

    18F-DOPA radioligand

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine which imaging technique (F-DOPA PET/CT, 68Ga-DOTATATE PET/CT, CT, and/or MRI) has the best sensitivity.Time frame: 6-12 months
  2. To determine if there is a combination of imaging tests with optimal diagnostic accuracy.Time frame: 6-12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Institutes of Health Clinical Center

    Bethesda, Maryland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.